Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 0.7% Following Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dropped 0.7% during mid-day trading on Monday following insider selling activity. The stock traded as low as $6.03 and last traded at $6.07. Approximately 1,184,366 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 5,826,398 shares. The stock had previously closed at $6.11.

Specifically, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total value of $123,200.00. Following the transaction, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at $4,697,960.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $6.22, for a total value of $71,200.34. Following the transaction, the director now directly owns 7,098,428 shares of the company’s stock, valued at approximately $44,152,222.16. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on RXRX. Needham & Company LLC decreased their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Jefferies Financial Group cut their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Finally, KeyCorp cut their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Stock Up 4.2 %

The stock has a fifty day moving average price of $6.79 and a 200 day moving average price of $7.98. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The stock has a market capitalization of $1.53 billion, a P/E ratio of -3.91 and a beta of 0.80.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. During the same quarter in the previous year, the firm earned ($0.38) earnings per share. The company’s revenue for the quarter was up 30.9% compared to the same quarter last year. On average, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Benjamin F. Edwards & Company Inc. purchased a new stake in Recursion Pharmaceuticals in the first quarter worth about $26,000. GAMMA Investing LLC boosted its stake in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after purchasing an additional 6,036 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares during the last quarter. Midwest Financial Group LLC bought a new stake in Recursion Pharmaceuticals in the 2nd quarter worth approximately $90,000. Finally, Xponance Inc. purchased a new stake in Recursion Pharmaceuticals during the 2nd quarter valued at $98,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.